Show simple item record

dc.contributor.authorSrivastava, Sukrit
dc.contributor.authorVerma, Sonia
dc.contributor.authorKamthania, Mohit
dc.contributor.authorAgarwal, Deepa
dc.contributor.authorSaxena, Ajay Kumar
dc.contributor.authorKolbe, Michael
dc.contributor.authorSingh, Sarman
dc.contributor.authorKotnis, Ashwin
dc.contributor.authorRathi, Brijesh
dc.contributor.authorNayar, Seema A
dc.contributor.authorShin, Ho-Joon
dc.contributor.authorVashisht, Kapil
dc.contributor.authorPandey, Kailash C
dc.date.accessioned2020-12-01T15:57:52Z
dc.date.available2020-12-01T15:57:52Z
dc.date.issued2020-11-06
dc.identifier.citationJ Biomol Struct Dyn. 2020 Nov 6:1-20. doi: 10.1080/07391102.2020.1838329. Epub ahead of print.en_US
dc.identifier.pmid33155524
dc.identifier.doi10.1080/07391102.2020.1838329
dc.identifier.urihttp://hdl.handle.net/10033/622626
dc.description.abstractThe SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is responsible for the COVID-19 outbreak. The highly contagious COVID-19 disease has spread to 216 countries in less than six months. Though several vaccine candidates are being claimed, an effective vaccine is yet to come. A novel reverse epitomics approach, 'overlapping-epitope-clusters-to-patches' method is utilized to identify the antigenic regions from the SARS-CoV-2 proteome. These antigenic regions are named as 'Ag-Patch or Ag-Patches', for Antigenic Patch or Patches. The identification of Ag-Patches is based on the clusters of overlapping epitopes rising from SARS-CoV-2 proteins. Further, we have utilized the identified Ag-Patches to design Multi-Patch Vaccines (MPVs), proposing a novel method for the vaccine design. The designed MPVs were analyzed for immunologically crucial parameters, physiochemical properties and cDNA constructs. We identified 73 CTL (Cytotoxic T-Lymphocyte) and 49 HTL (Helper T-Lymphocyte) novel Ag-Patches from the proteome of SARS-CoV-2. The identified Ag-Patches utilized to design MPVs cover 768 overlapping epitopes targeting 55 different HLA alleles leading to 99.98% of world human population coverage. The MPVs and Toll-Like Receptor ectodomain complex shows stable complex formation tendency. Further, the cDNA analysis favors high expression of the MPVs constructs in a human cell line. We identified highly immunogenic novel Ag-Patches from the entire proteome of SARS CoV-2 by a novel reverse epitomics approach and utilized them to design MPVs. We conclude that the novel MPVs could be a highly potential novel approach to combat SARS-CoV-2, with greater effectiveness, high specificity and large human population coverage worldwide.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectAg-Patch (antigenic patch)en_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectMulti-Epitope Vaccineen_US
dc.subjectMulti-Patch Vaccineen_US
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)en_US
dc.subjectToll-Like Receptor (TLR)en_US
dc.subjectepitopeen_US
dc.subjectoverlapping-epitope-clusters-to-patchesen_US
dc.subjectreverse epitomicsen_US
dc.titleComputationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide.en_US
dc.typeArticleen_US
dc.identifier.eissn1538-0254
dc.contributor.departmentCSSB, Centre for Structural Systembiologie, Notkestr.85, 22607 Hamburg. Germany.en_US
dc.identifier.journalJournal of biomolecular structure & dynamicsen_US
dc.source.beginpage1
dc.source.endpage20
refterms.dateFOA2020-12-01T15:57:52Z
dc.source.journaltitleJournal of biomolecular structure & dynamics
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Srivastava et al.pdf
Size:
5.592Mb
Format:
PDF
Description:
free file from the Taylor & ...

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International